JP6944780B2 - 速効型インスリン製剤及び医薬送達システム - Google Patents

速効型インスリン製剤及び医薬送達システム Download PDF

Info

Publication number
JP6944780B2
JP6944780B2 JP2016563903A JP2016563903A JP6944780B2 JP 6944780 B2 JP6944780 B2 JP 6944780B2 JP 2016563903 A JP2016563903 A JP 2016563903A JP 2016563903 A JP2016563903 A JP 2016563903A JP 6944780 B2 JP6944780 B2 JP 6944780B2
Authority
JP
Japan
Prior art keywords
insulin
pharmaceutical composition
composition according
position corresponding
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016563903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505338A5 (cg-RX-API-DMAC7.html
JP2017505338A (ja
Inventor
ジェフリー アイ. ジョセフ,
ジェフリー アイ. ジョセフ,
リチャード ウィリアム ベレンソン,
リチャード ウィリアム ベレンソン,
ブルース フランク,
ブルース フランク,
マイケル エー. ウェイス,
マイケル エー. ウェイス,
トーマス ハティヤー,
トーマス ハティヤー,
グレゴリー ドュベ,
グレゴリー ドュベ,
ジチャン チェン,
ジチャン チェン,
Original Assignee
サーマリン インコーポレイテッド
サーマリン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーマリン インコーポレイテッド, サーマリン インコーポレイテッド filed Critical サーマリン インコーポレイテッド
Publication of JP2017505338A publication Critical patent/JP2017505338A/ja
Publication of JP2017505338A5 publication Critical patent/JP2017505338A5/ja
Application granted granted Critical
Publication of JP6944780B2 publication Critical patent/JP6944780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/05Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02Holding devices, e.g. on the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448Drug reservoir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/01Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02Holding devices, e.g. on the body
    • A61M2025/0253Holding devices, e.g. on the body where the catheter is attached by straps, bands or the like secured by adhesives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/05General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/054General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
    • A61M2205/055General characteristics of the apparatus combined with other kinds of therapy with electrotherapy with electrophoresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/35Communication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/50General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502User interfaces, e.g. screens or keyboards
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/201Glucose concentration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
JP2016563903A 2014-01-13 2015-01-13 速効型インスリン製剤及び医薬送達システム Active JP6944780B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461926946P 2014-01-13 2014-01-13
US201461926944P 2014-01-13 2014-01-13
US61/926,946 2014-01-13
US61/926,944 2014-01-13
PCT/US2015/011202 WO2015106269A2 (en) 2014-01-13 2015-01-13 Rapid action insulin formulations and pharmaceutical delivery systems

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019014241A Division JP2019081773A (ja) 2014-01-13 2019-01-30 速効型インスリン製剤及び医薬送達システム
JP2020136982A Division JP2020189875A (ja) 2014-01-13 2020-08-14 速効型インスリン製剤及び医薬送達システム

Publications (3)

Publication Number Publication Date
JP2017505338A JP2017505338A (ja) 2017-02-16
JP2017505338A5 JP2017505338A5 (cg-RX-API-DMAC7.html) 2018-02-08
JP6944780B2 true JP6944780B2 (ja) 2021-10-06

Family

ID=53524484

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016563903A Active JP6944780B2 (ja) 2014-01-13 2015-01-13 速効型インスリン製剤及び医薬送達システム
JP2019014241A Pending JP2019081773A (ja) 2014-01-13 2019-01-30 速効型インスリン製剤及び医薬送達システム
JP2020136982A Pending JP2020189875A (ja) 2014-01-13 2020-08-14 速効型インスリン製剤及び医薬送達システム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019014241A Pending JP2019081773A (ja) 2014-01-13 2019-01-30 速効型インスリン製剤及び医薬送達システム
JP2020136982A Pending JP2020189875A (ja) 2014-01-13 2020-08-14 速効型インスリン製剤及び医薬送達システム

Country Status (10)

Country Link
US (4) US9901622B2 (cg-RX-API-DMAC7.html)
EP (1) EP3094343A4 (cg-RX-API-DMAC7.html)
JP (3) JP6944780B2 (cg-RX-API-DMAC7.html)
KR (1) KR102351111B1 (cg-RX-API-DMAC7.html)
CN (1) CN106102763A (cg-RX-API-DMAC7.html)
AU (1) AU2015204491B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016016290A2 (cg-RX-API-DMAC7.html)
CA (1) CA2936563A1 (cg-RX-API-DMAC7.html)
IL (1) IL246706B (cg-RX-API-DMAC7.html)
WO (1) WO2015106269A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2354107T3 (es) 2005-09-12 2011-03-10 Unomedical A/S Dispositivo de inserción para un equipo de infusión con una primera y segunda unidades de resorte.
WO2011121023A1 (en) 2010-03-30 2011-10-06 Unomedical A/S Medical device
WO2012123274A1 (en) 2011-03-14 2012-09-20 Unomedical A/S Inserter system with transport protection
US11197689B2 (en) 2011-10-05 2021-12-14 Unomedical A/S Inserter for simultaneous insertion of multiple transcutaneous parts
EP2583715A1 (en) 2011-10-19 2013-04-24 Unomedical A/S Infusion tube system and method for manufacture
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
JP6944780B2 (ja) 2014-01-13 2021-10-06 サーマリン インコーポレイテッド 速効型インスリン製剤及び医薬送達システム
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
US10822386B2 (en) * 2014-12-24 2020-11-03 Case Western Reserve University Insulin analogues with enhanced stability and reduced mitogenicity
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US11357912B2 (en) 2016-01-19 2022-06-14 Unomedical A/S Cannula and infusion devices
EP3541397A4 (en) * 2016-11-21 2020-11-04 Case Western Reserve University FAST-ACTING INSULIN ANALOGUE WITH IMPROVED STABILITY
TW201835099A (zh) * 2017-03-07 2018-10-01 美國凱斯西方瑞瑟夫大學 藉由第四雙硫鍵穩定之單鏈胰島素類似物
GB201707187D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
KR20190140048A (ko) 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
US11510967B2 (en) 2017-09-08 2022-11-29 Eli Lilly And Company Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
EP3773474B1 (en) * 2018-04-04 2026-01-07 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN113166223A (zh) * 2018-09-21 2021-07-23 卡斯西部储备大学 位点2单链胰岛素类似物
AU2020279968A1 (en) * 2019-05-17 2021-12-16 Case Western Reserve University Variant single-chain insulin analogues
WO2020236796A1 (en) 2019-05-20 2020-11-26 Unomedical A/S Rotatable infusion device and methods thereof
US20220379022A1 (en) * 2019-10-30 2022-12-01 Thermalin, Inc. Agent delivery systems, devices, and methods
NL2025679B1 (en) * 2020-05-26 2021-12-13 Johanna Daams Brechtje Electrical stimulation for preventing or treating nitric oxide deficiency related conditions
CA3190574A1 (en) 2020-08-23 2022-03-03 William Kenneth Ward Measurement of glucose near an insulin delivery catheter by minimizing the adverse effects of insulin preservatives: alternative ligands and redox mediator metals
US20220386905A1 (en) * 2021-03-02 2022-12-08 Pacific Diabetes Technologies Inc Signal processing algorithm for improving accuracy of a continuous glucose sensor and a combined continuous glucose sensor and insulin delivery cannula
KR102678960B1 (ko) * 2021-08-26 2024-06-27 주식회사 에이피알 바디 관리기
US20240149021A1 (en) * 2022-11-04 2024-05-09 Becton, Dickinson And Company Intravenous Catheter Securement Sleeve
US20240216649A1 (en) * 2023-01-03 2024-07-04 Becton, Dickinson And Company Management of Catheters and Accessories During Intravascular Catheter Maintenance
US20250242110A1 (en) * 2024-01-26 2025-07-31 Medtronic Minimed, Inc. Fluid delivery filters

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK134691D0 (da) * 1991-07-12 1991-07-12 Novo Nordisk As Apparat
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EP1196445A1 (en) * 1999-06-29 2002-04-17 Eli Lilly And Company Insulin crystals for pulmonary administration
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
AU2008233220B2 (en) * 2007-03-30 2013-01-10 Instrumentation Laboratory Company Adaptor for sample vial
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
KR20110021758A (ko) 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
EP2318432B1 (en) * 2008-07-31 2015-09-02 Case Western Reserve University Halogen-stabilized insulin
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US8481485B2 (en) * 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2011028813A2 (en) 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
MX2012006568A (es) 2009-12-11 2012-12-17 Univ Case Western Reserve Analogos de insulina con aminoacidos clorados.
US20130085101A1 (en) 2010-02-22 2013-04-04 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
WO2013010048A2 (en) 2011-07-13 2013-01-17 Case Western Reserve University Non-standard insulin analogues
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS
PL2773331T3 (pl) * 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Preparaty do leczenia cukrzycy
EP2804621A4 (en) * 2012-01-20 2015-11-18 Univ Case Western Reserve GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US9624287B2 (en) 2012-07-17 2017-04-18 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
WO2014071405A2 (en) 2012-11-05 2014-05-08 Case Western Reserve University Long-acting single-chain insulin analogues
JP2016506927A (ja) 2013-01-22 2016-03-07 ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University N末端短縮型インスリン類似体
BR112015023672A2 (pt) 2013-03-15 2017-07-18 Univ Case Western Reserve análogo de insulina, orto-fluoro, sequência de dna codificando a cadeia a de análogo de insulina, sequência de dna codificando a cadeia b de análogo de insulina e uso de um análogo de insulina.
JP6944780B2 (ja) 2014-01-13 2021-10-06 サーマリン インコーポレイテッド 速効型インスリン製剤及び医薬送達システム
CN107108716A (zh) 2014-10-06 2017-08-29 卡斯西部储备大学 双相性单链胰岛素类似物
JP2017537065A (ja) 2014-10-20 2017-12-14 ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University 生物学的作用強度の高いハロゲン化インスリン類似体
US10822386B2 (en) 2014-12-24 2020-11-03 Case Western Reserve University Insulin analogues with enhanced stability and reduced mitogenicity
BR112017015608A2 (pt) 2015-01-20 2018-03-13 Univ Case Western Reserve análogos de insulina com propriedades de sinalização seletiva e reduzida mitogenicidade

Also Published As

Publication number Publication date
US10561711B2 (en) 2020-02-18
US20180243380A1 (en) 2018-08-30
EP3094343A2 (en) 2016-11-23
IL246706A0 (en) 2016-08-31
EP3094343A4 (en) 2017-10-18
IL246706B (en) 2020-04-30
WO2015106269A3 (en) 2015-10-22
CN106102763A (zh) 2016-11-09
BR112016016290A2 (pt) 2017-10-03
WO2015106269A2 (en) 2015-07-16
JP2017505338A (ja) 2017-02-16
US9901622B2 (en) 2018-02-27
US20200138911A1 (en) 2020-05-07
CA2936563A1 (en) 2015-07-16
KR20160122145A (ko) 2016-10-21
US20160375104A1 (en) 2016-12-29
AU2015204491B2 (en) 2021-01-07
US20210386831A1 (en) 2021-12-16
AU2015204491A1 (en) 2016-08-18
KR102351111B1 (ko) 2022-01-14
WO2015106269A8 (en) 2016-08-18
JP2020189875A (ja) 2020-11-26
JP2019081773A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
JP6944780B2 (ja) 速効型インスリン製剤及び医薬送達システム
Wong et al. Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities
JP6422855B2 (ja) インスリンおよびインスリン類似体の薬物動態及び薬力学、ならびに注射部位の疼痛を調節するためのマグネシウム組成物
JP6763777B2 (ja) 安定なペプチド製剤、および調製のための方法
RS59423B1 (sr) Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
Woo New insulins and new aspects in insulin delivery
CN101951888B (zh) 治疗性蛋白质的功效的增强
KR102833828B1 (ko) 인슐린 화합물의 전달을 위한 의료용 주입 펌프 시스템
CN105579052A (zh) 药物组合物
IL277720B2 (en) Medical infusion pump system for the delivery of an insulin compound
JP2020527396A (ja) 先天性高インスリン症を処置する方法
JP2021506933A (ja) 1型糖尿病およびインスリン使用2型糖尿病における運動誘発性低血糖の処置
AU2013368990A1 (en) Pharmaceutical composition
US20250276127A1 (en) Therapeutic methods and devices
CA3094308C (en) Medical infusion pump system for the delivery of an insulin compound
KR20250103637A (ko) 비양성자성 극성 용매를 사용한 서방형 주사용 제형
JP2023522944A (ja) 1型糖尿病患者に優れた血糖制御をもたらすためのヒトアミリンアナログポリペプチドの使用
HK1151241B (en) Enhancement of the efficacy of therapeutic proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200814

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200915

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200914

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200915

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201106

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201110

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210706

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210810

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210909

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210913

R150 Certificate of patent or registration of utility model

Ref document number: 6944780

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250